| Colao, Annamaria AL |
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk |
|
|
| Active, not recruiting | 3 | 2749 | Europe, US, RoW | Orforglipron, LY3502970, Insulin Glargine | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease | 09/25 | 01/26 | | |
SIDERALE2020, NCT06236932: Susceptibility to Infectious Diseases in obEsity: an endocRine trAnslational socioLogic Evaluation, "SIDERALE" |
|
|
| Recruiting | N/A | 100 | Europe | Mediterranean diet, Melatonin supplementation | Federico II University, University of Roma La Sapienza, University of Pisa, Università degli Studi del Piemonte Orientale "Amedeo Avogadro", University of Rome Foro Italico | Obesity, Type2diabetes, Lipodystrophy, Infections, Obesity Associated Disorder | 12/24 | 05/25 | | |
LO-COCO, NCT05293366: LOng COvid COmorbidities: Endocrine,Metabolic,Neuropsychiatric,Muscle,Cardiovascular,Pulmonary,Dermatologic Dysfunctions |
|
|
| Recruiting | N/A | 100 | Europe | Assessments of endocrinological phenotypes of LO-COCO patients, Evaluation of hormonal and metabolic health, Assessment of muscular phenotypes of LO-COCO patients, Assessment of neuropsychiatric phenotypes of LO-COCO patients, Muscle biopsy, Assessment of pulmonary phenotypes of LO-COCO patients, Assessment of cardiological phenotypes of LO-COCO patients, Assessment of vascular phenotypes of LO-COCO patients, Assessment of dermatological phenotypes of LO-COCO patients, Tissue biopsy | Federico II University, Azienda Sanitaria Locale Napoli 2 Nord | Long Covid-19 | 01/25 | 01/26 | | |
NCT06645951: Institution of an Italian Multicenter Database of Patients With Parathyroid Carcinoma or Atypical Parathyroid Adenoma |
|
|
| Not yet recruiting | N/A | 300 | Europe | | F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore | Parathyroid Gland Carcinoma, Parathyroid Gland Atypical Adenoma | 11/34 | 11/34 | | |
NCT06645899: Institution of an Italian Multicenter Database of Patients Affected by Hypoparathyroidism or Pseudohypoparathyroidism |
|
|
| Not yet recruiting | N/A | 600 | Europe | | F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore | Hypoparathyroidism, Pseudo Hypoparathyroidism | 11/34 | 11/34 | | |
| Recruiting | N/A | 3600 | Europe | | Italian Association Neuroendocrine Tumors | Gastro-entero Pancreatic Neuroendocrine Tumors | 07/27 | 07/32 | | |
| Zhang, Jin li |
NCT03359694: Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer |
|
|
| Not yet recruiting | 3 | 300 | RoW | DT group, Pegylated liposomal doxorubicin and Docetaxel, ET group, Conventional doxorubicin and Docetaxel, NX group, Navelbine and Xeloda | Tianjin Medical University Cancer Institute and Hospital | Susceptibility, Genetic, Chemotherapy Effect | 11/19 | 10/22 | | |
NCT04629846: Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel. |
|
|
| Completed | 3 | 517 | RoW | Trastuzumab, Herceptin®, QL1209, Recombinant anti-HER-2 domain Ⅱ humanized monoclonal antibody injection, Pertuzumab, Perjeta®, Docetaxel, Docetaxel injection, surgery | Qilu Pharmaceutical Co., Ltd. | Breast Cancer | 08/22 | 10/23 | | |
CLOVER, NCT03926091: Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer |
|
|
| Recruiting | 3 | 2172 | RoW | Docetaxel, docetaxel injection, Cyclophosphamide, Cyclophosphamide injection | Fudan University | Breast Cancer | 11/24 | 11/25 | | |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
BELIEVE-01, NCT05234684: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 3 | 150 | RoW | Orelabrutinib + R-CHOP, ICP-022+ R-CHOP, Placebo + R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma (DLBCL) | 07/24 | 12/25 | | |
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
NCT03351062: Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer |
|
|
| Recruiting | 3 | 844 | RoW | Tamoxifen, Tamoxifen citrate, Toremifene, fareston | Chinese Anti-Cancer Association, Fudan University, Henan Cancer Hospital, The First Hospital of Jilin University, Southwest Hospital, China, First Hospital of China Medical University, Guangdong Provincial People's Hospital, Harbin Medical University, First Affiliated Hospital of Chongqing Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Jiangsu Provincial People's Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Zhejiang Cancer Hospital, Tianjin Medical University Cancer Institute and Hospital, Union hospital of Fujian Medical University, Hebei Tumor Hospital, Hunan Cancer Hospital, Affiliated Hospital of Qinghai University, Wuhan TongJi Hospital, Hainan People's Hospital, The Third Affiliated Hospital of Kunming Medical College., The Third Affiliated Hospital of Nanchang University | Breast Cancer Female | 12/25 | 12/25 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
NCT06227117: Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer |
|
|
| Recruiting | 2 | 120 | RoW | Disitamab Vedotin Injection （18 weeks）, DV,RC48-ADC, Toripalimab （18weeks）, JS001, Carboplatin, Disitamab Vedotin Injection （12 weeks）, Sequential Epirubicin, Epirubicin, Sequential CTX, CTX, cyclophosphamide, Toripalimab （12weeks） | RemeGen Co., Ltd. | Breast Cancer | 12/25 | 12/26 | | |
NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis |
|
|
| Active, not recruiting | 2 | 112 | Europe, US, RoW | Selinexor, Physician's Choice Treatment | Karyopharm Therapeutics Inc | Myelofibrosis | 01/25 | 01/25 | | |
|
|
NCT03955978: TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer |
|
|
| Active, not recruiting | 1 | 10 | US | TSR-042, Brachytherapy, Endometrial biopsy, Blood draw for immune response | Washington University School of Medicine, Tesaro, Inc. | Endometrial Cancer, Cancer of the Endometrium | 03/24 | 12/25 | | |
| Not yet recruiting | N/A | 402 | NA | S-ketamine, esketamine, normal saline, physiological saline | Beijing Obstetrics and Gynecology Hospital, China Health Promotion Foundation, Beijing Haidian Maternal and Child Health Hospital, Obstetrics & Gynecology Hospital of Fudan University, Fourth Hospital of Shijiazhuang City, Changzhi Maternal and Child Health Hospital, Linfen Maternity&Child Healthcare Hospital, Maternal and Child Health Hospital, Jiading District, Tongzhou Maternal and Child Healthcare Hospital of Beijing, Beijing Chaoyang District Maternal and Child Health Care Hospital | Anesthesia, Analgesia, Depression, Cesarean Section, Parturition | 12/21 | 07/22 | | |
NCT04940091: Epidural Analgesia and Maternal Fever During Labor |
|
|
| Recruiting | N/A | 780 | RoW | Epidural analgesia, No other intervention | Peking University First Hospital, Guangdong Women and Children Hospital, Tangshan Maternal and Child Health Hospital, Dongguan Maternal and Child Health Hospital, Beijing Haidian Maternal and Child Health Hospital, Beijing Fuxing Hospital, Fourth Hospital of Shijiazhuang City, Xiamen Maternity & Child Care Hospital | Epidural Analgesia, Analgesic Effect, Fever | 09/22 | 10/22 | | |
NCT04582955: Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy |
|
|
| Recruiting | N/A | 20 | RoW | Chidamide in combination with chemotherapy, Other Name: For Chidamide: HBI-8000, CS055 | Tianjin Medical University Cancer Institute and Hospital | Triple-negative Breast Cancer | 12/22 | 12/22 | | |
NCT02506361: Evaluation of the Relationship of TOP2α Expression and Effect of Non Dose-dense Chemotherapy for Breast Cancer |
|
|
| Recruiting | N/A | 800 | RoW | | Tianjin Medical University Cancer Institute and Hospital | Breast Cancer | 05/25 | 10/25 | | |
NCT05534854: Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes |
|
|
| Recruiting | N/A | 500 | RoW | Gene test | RenJi Hospital, Ruijin Hospital, Shanghai Zhongshan Hospital, Huashan Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Zhejiang Provincial People's Hospital, Tongji Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University, Shanghai 10th People's Hospital, First Affiliated Hospital, Sun Yat-Sen University, Peking University First Hospital | Renal Tumor Histology, Kidney Cancer, Renal Cell Carcinoma, Familial Renal Cancer, HLRCC, VHL Syndrome, BAP1 Tumor Predisposition Syndrome, FLCN Gene Mutation, ALK Gene Mutation, FH Gene Mutation, Birt-Hogg-Dube Syndrome, MET Gene Mutation, Cutaneous Leiomyoma, Cutaneous Leiomyomata With Uterine Leiomyomata | 08/25 | 08/25 | | |
| Canani, Roberto Berni |
| Recruiting | 2 | 230 | Europe, Canada, US | DBV1605 | DBV Technologies | Cow's Milk Allergy | 03/24 | 03/24 | | |
NCT04652388: Impact of Nutritional Counselling in Children With Autism |
|
|
| Recruiting | N/A | 20 | Europe | Nutritional counseling | Federico II University | Autism Spectrum Disorder | 09/20 | 09/22 | | |
| Recruiting | N/A | 120 | Europe | Obese with or without metabolic syndromesubjects | Federico II University | Obesity, Childhood, Metabolic Syndrome | 05/22 | 05/22 | | |
NCT04740632: The Quality of Life of Mothers of Children With Food Allergy |
|
|
| Recruiting | N/A | 100 | Europe | Personalized Nutritional Counseling by a multidisciplinary team | Federico II University | Food Allergy | 06/22 | 01/23 | | |
NCT06139185: The ARHINASD (Allergic Rhinitis in Pediatric Subjects With Nasal Septum Deviation) Project |
|
|
| Recruiting | N/A | 69 | Europe | Data collection | Federico II University | Rhinitis, Allergic | 01/24 | 01/24 | | |
NCT05901220: Joint School-Health Project of the Neapolitan Child |
|
|
| Completed | N/A | 223 | Europe | Healthy lifestyle | Federico II University | No Condition | 06/23 | 06/23 | | |
NCT06152835: The BuKoBc Project: Building a Deeper Knowledge on Breast Milk Composition |
|
|
| Recruiting | N/A | 100 | Europe | Data and breast milk samples collection | Federico II University | Breastfeeding | 07/26 | 07/26 | | |
NCT06152848: The SAM Project: Science Against Malnutrition Project |
|
|
| Recruiting | N/A | 2000 | Europe | Data and samples collection | Federico II University | Malnutrition | 07/26 | 07/26 | | |
| Recruiting | N/A | 200 | Europe | | Federico II University | Obesity, Morbid, Metabolic Syndrome | 09/23 | 09/23 | | |
| Recruiting | N/A | 150 | Europe | Non IgE-mediated food allergy | Federico II University | Non IgE Mediated Food Allergy, Food Protein-Induced Enteropathy, Food Protein-Induced Proctocolitis, Food Protein-Induced Enterocolitis Syndrome, Food Protein-induced Motility Disorders | 12/23 | 12/25 | | |
| Recruiting | N/A | 90 | Europe | EHCF+LGG, RHF, SF, EHWF, AAF | Federico II University | Cow Milk Allergy | 12/23 | 08/24 | | |
| Completed | N/A | 29 | Europe | Liquid Extensively hydrolyzed cow's milk protein infant formula | Federico II University | Allergy, Cow's Milk Allergy | 07/24 | 07/24 | | |
b(AUT)yrate, NCT06514573: Butyrate Supplementation in Children With Autism Spectrum Disorder (ASD) and Functional Gastrointestinal Disorders |
|
|
| Not yet recruiting | N/A | 128 | Europe | Sodium Butyrate, Placebo (cornstarch) | Istituto Superiore di Sanità, University of Rome Tor Vergata, Federico II University | Autism Spectrum Disorder (ASD) | 05/25 | 07/25 | | |
RIGHT-HY, NCT06633289: Hypoallergenicity of a Hydrolyzed Rice Protein-based Formula in Infants and Young Children With Cow's Milk Protein Allergy |
|
|
| Not yet recruiting | N/A | 67 | Europe | Experimental formula, Control formula | Société des Produits Nestlé (SPN) | Cow's Milk Protein Allergy | 09/26 | 10/26 | | |
RIGHT-GO, NCT06633250: Effect of a Hydrolyzed Rice Protein-based Formula on Growth, Tolerance, and Health-related Quality of Life in Infants With Cow's Milk Protein Allergy. |
|
|
| Not yet recruiting | N/A | 104 | Europe | Test Formula, Control Formula | Société des Produits Nestlé (SPN) | Cow Milk Protein Allergy | 02/26 | 02/26 | | |
PREMEDI, NCT05119868: Effects of the Mediterranean Diet During Pregnancy on the Onset of Allergies in the Offspring |
|
|
| Recruiting | N/A | 276 | Europe | Nutritional intervention based on Mediterranean Diet | Federico II University | Allergies, Obesity, Gestational Complications, Gestational Weight Gain, Perinatal Condition, Birth Weight, Chronic Diseases in Children, Breast Feeding | 01/25 | 01/26 | | |
NCT06093204: The Potential Role of Compounds Derived From Ultra-processed Foods in Pathogenesis of Eosinophilic Esophagitis |
|
|
| Recruiting | N/A | 80 | Europe | Dietary evaluation | Federico II University | Esophagitis, Eosinophilic | 04/25 | 04/25 | | |
| Recruiting | N/A | 300 | Europe | | Federico II University | Child Malnutrition, Child Allergy, Maternal Exposure | 05/26 | 05/26 | | |
| Recruiting | N/A | 600 | Europe | Development of the NAPFA score | Federico II University | Food Allergy in Children | 06/23 | 12/23 | | |
| Staiano, Annamaria |
NCT04283864: Decoding Personalized Nutritional, Microbiome and Host Patterns Impacting Clinical and Prognostic Features in Crohn's Disease |
|
|
| Recruiting | N/A | 300 | Europe, RoW | | Weizmann Institute of Science, The Leona M. and Harry B. Helmsley Charitable Trust | Crohn Disease | 12/25 | 12/25 | | |
NCT05340712: Evaluation of the Efficacy of a New Specific Infant Formula in Case of Functional Constipation |
|
|
| Recruiting | N/A | 80 | Europe | new infant formula, Standard formula, Novalac 1 | United Pharmaceuticals, Delta Consultants | Functional Constipation | 12/23 | 09/24 | | |
NCT05904938: Oral Administration of Actitan-F in Paediatric Diarrhoea |
|
|
| Recruiting | N/A | 136 | Europe | Lenodiar Pediatric, Placebo | Aboca Spa Societa' Agricola, IQVIA RDS, IQVIA Solutions | Chronic Diarrhoea of Infants and/or Young Children | 12/24 | 12/24 | | |
| Placido, Sabino De |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 866 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 06/24 | 08/27 | | |
| Active, not recruiting | 3 | 654 | Europe, Canada, Japan, US, RoW | Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo | Seagen Inc., Merck Sharp & Dohme LLC | HER2 Positive Breast Cancer | 05/25 | 10/27 | | |
|
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
NCT05266937: Atezolizumab Plus CArboplatin Plus Nab-paclitaxel |
|
|
| Active, not recruiting | 2 | 49 | Europe | Atezolizumab,Paclitaxel, Carboplatin | Consorzio Oncotech | Metastatic Breast Cancer, Triple Negative Breast Cancer, PD-L1 Gene Mutation | 07/24 | 07/24 | | |
BREAKFAST-2, NCT05763992: Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial |
|
|
| Recruiting | 2 | 145 | Europe | Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Istituto Oncologico Veneto IRCCS, Ospedale Policlinico San Martino, Federico II University, Azienda Policlinico Umberto I, European Institute of Oncology, Ospedale "Carlo Poma" - Mantova, Humanitas Clinical and Research Center | Breast Cancer, Triple Negative Breast Cancer, Dietary Exposure, Fasting | 05/25 | 05/26 | | |
| Recruiting | N/A | 15000 | Europe | Data collection (retrospective), Data collection (prospective) | National Cancer Institute, Naples | Oncology | 01/25 | 07/26 | | |
NCT05754502: Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy |
|
|
| Recruiting | N/A | 300 | Europe | Trastuzumab emtansine | Consorzio Oncotech, Roche Pharma AG | Breast Cancer | 09/24 | 05/25 | | |
| Recruiting | N/A | 1000 | Europe | | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Clinical Research Technology S.r.l. | Breast Neoplasms, Pregnancy, Fertility Preservation | 11/27 | 11/32 | | |
| Esposito, Giovanni |
| Recruiting | 4 | 2500 | Europe, RoW | Pressure Microcatheter guided strategy - PIOS MC, Pressure Wire guided strategy - PIOS - PW, Pressure Microcatheter guided strategy - Standard of care, Pressure Wire guided strategy - Standard of care | CoreAalst BV, Insight Lifetech Co., Ltd. | Coronary Artery Disease, Acute Coronary Syndrome | 06/26 | 06/30 | | |
MIRACOR, NCT06089577: Effects of Cangrelor on MIcRovAscular Disfunction During Elective Percutaneous CORonary Intervention |
|
|
| Recruiting | 4 | 80 | NA | Cangrelor 50 MG | Federico II University | Coronary Artery Disease | 10/25 | 10/26 | | |
INOCAIT, NCT05164640: Ischemia in Patients With Non-obstructive Disease (INOCA) in Italy INOCA IT Multicenter Registry" |
|
|
| Completed | N/A | 200 | Europe | not required | IRCCS San Raffaele, Advice Pharma Group srl | Cardiac Ischemia | 02/24 | 02/24 | | |
| Active, not recruiting | N/A | 2001 | Europe | QFR-based diagnostic strategy, FFR-based diagnostic strategy | Aarhus University Hospital Skejby, Medis Medical Imaging Systems | Coronary Artery Disease | 07/23 | 12/25 | | |
POMPEII, NCT04790032: Pharmacodynamic Effects of Cangrelor in ACS or CCS Patients Undergoing PCI ( Registry) |
|
|
| Recruiting | N/A | 100 | Europe | Cangrelor | Federico II University | Percutaneous Coronary Intervention | 10/24 | 10/24 | | |
NCT06162247: Naples Federico II Intensive Cardiac Care Unit Registry (Naples FED2-ICCU Registry) |
|
|
| Recruiting | N/A | 5000 | Europe | | Federico II University | Acute Cardiovascular Disease, Acute Coronary Syndrome, Acute Heart Failure, Cardiogenic Shock | 11/33 | 11/33 | | |
| Recruiting | N/A | 190 | Europe | Thermodilution based assessment of coronary microcirculation | Azienda Ospedaliera Universitaria Integrata Verona, Abbott Medical Devices | Heart Failure, Left Ventricular Dysfunction, Idiopathic Dilated Cardiomyopathy | 01/26 | 01/30 | | |
ITACA, NCT05051917: The Italian Coronary Artery Aneurysm and Ectasia In Patients With Acute Coronary Syndrome |
|
|
| Recruiting | N/A | 500 | Europe | | Federico II University, Fondazione GISE Onlus | Acute Coronary Syndrome, Angiographic Evidence if Coronary Aneurysms, Ectasia | 09/24 | 09/26 | | |
| Recruiting | N/A | 1000 | Europe | Transcatheter heart valve (THV) with CE approval | Federico II University | Aortic Stenosis, Transcatheter Aortic Valve Replacement, TAVI | 09/21 | 01/30 | | |
| Completed | N/A | 200 | Europe | Fractional Flow Reserve, RFR, Pd/Pa | Federico II University | Coronary Artery Disease | 07/22 | 07/22 | | |
MiVa, NCT05686707: Characterization of Different Phenotypes of Microvascular Dysfunction and Their Impact on Angina Severity in Patients With Chronic Angina in the Absence of Obstructive Coronary Artery Disease. |
|
|
| Recruiting | N/A | 400 | Europe | | Federico II University, University of Catanzaro, I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio, Università degli Studi di Ferrara, IRCCS Multimedica, Università di Siena, University of Parma, Universita di Verona, Ospedale Policlinico San Martino, Genova, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Azienda Policlinico Umberto I, Azienda Ospedaliero-Universitaria Careggi | Angina CCS Classe II-IV - IMR, RFR, FFR,CFR | 12/24 | 06/25 | | |
| Pivonello, Rosario |
| Recruiting | 4 | 150 | Europe | Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone), Dual release hydrocortisone (plenadren) | Federico II University | Congenital Adrenal Hyperplasia | 12/23 | 12/23 | | |
| Recruiting | 2 | 32 | Europe | Lutropin alfa, LH, Human chorionic gonadotropin, hCG | Azienda Ospedaliero-Universitaria di Modena | Acquired Hypogonadotropic Hypogonadism | 01/25 | 01/26 | | |
LO-COCO-ANDRO, NCT05379556: LOng COvid COmorbidities: Andrological, Reproductive, Sexual Dysfunctions in Patients Recovered From COVID-19 |
|
|
| Recruiting | N/A | 100 | Europe | Assessment of andrological profile of LO-COCO-ANDRO male patients, Assessment of reproductive function of LO-COCO-ANDRO male patients, Assessment of sexual function of LO-COCO-ANDRO male patients, Assessment of olfactory function of LO-COCO-ANDRO male and female patients | Federico II University, Azienda Sanitaria Locale Napoli 2 Nord | Long Covid-19 | 01/25 | 01/26 | | |
| Martino, Maria Cristina De |
| Recruiting | 4 | 150 | Europe | Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone), Dual release hydrocortisone (plenadren) | Federico II University | Congenital Adrenal Hyperplasia | 12/23 | 12/23 | | |
| Saccone, Gabriele |
COLORS, NCT03251729: Cerclage On LOw Risk Singletons: Cervical Cerclage for Prevention of Spontaneous Preterm Birth in Low Risk Singleton Pregnancies With Short Cervix |
|
|
| Completed | 4 | 93 | Europe, US | Cervical cerclage, Vaginal progesterone | Thomas Jefferson University | Premature Birth | 02/24 | 02/24 | | |
NCT04662424: Effect of Music in Labor in Women Who Underwent Induction of Labor |
|
|
| Recruiting | N/A | 30 | Europe | music in labor | Federico II University | Labor Pain | 02/21 | 03/21 | | |
NCT02923973: Transvaginal Ultrasound Cervical Length Screening in Singleton Pregnancy With Prior Spontaneous Preterm Birth |
|
|
| Recruiting | N/A | 500 | Europe | Transvaginal ultrasound cervical length screening | Federico II University, University of Pisa - Prof Paolo Mannella | Preterm Birth | 12/24 | 03/25 | | |
NCT03591042: Universal Transvaginal Cervical Length Screening Program for Prevention of Preterm Birth in Singletons Without Prior Preterm Birth |
|
|
| Recruiting | N/A | 1334 | Europe | cervical length screening | Federico II University | Preterm Birth | 12/21 | 03/22 | | |
NCT04205292: Cesarean Scar Pregnancy Managed by Dilatation and Evacuation (D&E) Versus Hysteroscopic Surgery |
|
|
| Recruiting | N/A | 54 | Europe | hysteroscopic | Federico II University | Scar; Previous Cesarean Section | 12/21 | 01/22 | | |
| Recruiting | N/A | 100 | Europe | PREGNOLIA SYSTEM | Federico II University | Preterm Labor, Preterm Birth | 09/22 | 12/22 | | |
NCT05449171: High Molecular Weight Hyaluronic Acid, α-lipoic Acid, Magnesium, Vitamin B6 and Vitamin D, in the Prevention of Spontaneous Abortion |
|
|
| Completed | N/A | 100 | Europe | high molecular weight hyaluronic acid, α-lipoic acid (ALA), magnesium, vitamin B6 and vitamin D | Lo.Li.Pharma s.r.l | Abortion, Spontaneous | 09/23 | 01/24 | | |
NCT06355375: Exercise in Pregnancy and Risk of Postpartum Depression |
|
|
| Recruiting | N/A | 398 | Europe | exercise in pregnancy | Federico II University | Depression, Pregnancy Related | 01/25 | 12/25 | | |
| Recruiting | N/A | 40 | Europe | Molecular and genetic screening | Federico II University, San Raffaele University Hospital, Italy, San Giuseppe Moscati Hospital | Peripartum Cardiomyopathy | 02/25 | 05/26 | | |
| Recruiting | N/A | 200 | Europe, US, RoW | Cervical cerclage | Thomas Jefferson University, Federico II University | Twin Pregnancy With Antenatal Problem, Preterm Birth, Short Cervix | 06/24 | 06/25 | | |
| Milone, Marco |
CORE1, NCT05726188: Predictors of Disease Recurrence After Curative Surgery for Stage I Colon Cancer |
|
|
| Recruiting | N/A | 2000 | Europe | Colonic resection | Azienda Ospedaliera Universitaria Integrata Verona | Colon Cancer Stage I, Colon Cancer | 09/23 | 09/23 | | |
| Aizenberg, Diego |
SURPASS-EARLY, NCT05433584: A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes |
|
|
| Active, not recruiting | 4 | 780 | Europe, Canada, US, RoW | Tirzepatide, LY3298176, Antihyperglycemic medication | Eli Lilly and Company | Type 2 Diabetes | 10/25 | 11/27 | | |
TRANSCEND-T2D-2, NCT06260722: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor |
|
|
| Recruiting | 3 | 1250 | Canada, US, RoW | Retatrutide, LY3437943, Semaglutide | Eli Lilly and Company | Diabetes Mellitus, Type 2 | 12/26 | 03/27 | | |
NCT06297603: Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) |
|
|
| Recruiting | 3 | 320 | Europe, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Type 2 Diabetes | 09/26 | 10/26 | | |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | 02/29 | 02/29 | | |
QWINT-1, NCT05662332: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time |
|
|
| Completed | 3 | 795 | US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Glargine | Eli Lilly and Company | Type 2 Diabetes, T2D | 07/24 | 07/24 | | |
ATTAIN-OSA, NCT06649045: A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight |
|
|
| Recruiting | 3 | 600 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | OSA, Overweight or Obesity | 11/26 | 01/27 | | |
TRIUMPH-5, NCT06662383: A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity |
|
|
| Recruiting | 3 | 800 | Europe, US, RoW | Retatrutide, LY3437943, Tirzepatide, LY3298176 | Eli Lilly and Company | Obesity | 04/27 | 04/27 | | |
SURMOUNT-5, NCT05822830: A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities |
|
|
| Completed | 3 | 751 | US | Tirzepatide, LY3298176, Semaglutide | Eli Lilly and Company | Obesity, Overweight | 11/24 | 11/24 | | |
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk |
|
|
| Active, not recruiting | 3 | 2749 | Europe, US, RoW | Orforglipron, LY3502970, Insulin Glargine | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease | 09/25 | 01/26 | | |
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 1576 | Japan, US, RoW | Orforglipron, LY3502970, Semaglutide | Eli Lilly and Company | Type 2 Diabetes | 09/25 | 09/25 | | |
| Active, not recruiting | 3 | 1800 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Obesity, Cardiovascular Diseases | 01/26 | 02/26 | | |
TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight |
|
|
| Active, not recruiting | 3 | 1000 | Europe, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea | 05/26 | 05/26 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
NCT06143956: A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight |
|
|
| Recruiting | 2 | 1040 | US, RoW | LY3305677, LY3841136, Tirzepatide, Placebo, LY3549492 | Eli Lilly and Company | Obesity, Overweight | 06/26 | 09/26 | | |
NCT06230523: A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight |
|
|
| Recruiting | 2 | 250 | US, RoW | LY3841136, Placebo | Eli Lilly and Company | Obesity, Overweight and Obesity | 06/25 | 09/25 | | |
NCT06603571: A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes |
|
|
| Recruiting | 2 | 350 | US, RoW | LY3841136, Tirzepatide, Placebo | Eli Lilly and Company | Obesity, Overweight | 06/26 | 08/26 | | |
NCT06683508: A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight |
|
|
| Recruiting | 2 | 275 | US, RoW | LY3549492, Placebo | Eli Lilly and Company | Obesity, Overweight | 04/26 | 09/26 | | |
NCT06037252: A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity |
|
|
| Recruiting | 2 | 350 | US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Type 2 Diabetes, Obesity | 01/26 | 10/26 | | |
| Li, Zhihua |
NCT04300114: A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy |
|
|
| Terminated | 3 | 5 | RoW | Fluzoparib, SHR3162, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Pancreatic Cancer | 02/22 | 02/22 | | |
| Active, not recruiting | 3 | 408 | RoW | KN046, placebo | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Pancreatic Ductal Adenocarcinoma | 04/24 | 08/24 | | |
G-HOPE-001, NCT06238843: A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Enrolling by invitation | 3 | 450 | RoW | irinotecan, IBI343, paclitaxel | Innovent Biologics (Suzhou) Co. Ltd. | Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | 12/26 | 12/27 | | |
NCT02062489: Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients |
|
|
| Recruiting | 3 | 688 | RoW | Tamoxifen, Nolvadex, Placebo | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Breast Cancer | 05/25 | 05/26 | | |
